Log in

NASDAQ:ALKSAlkermes Stock Price, Forecast & News

$15.43
-0.40 (-2.53 %)
(As of 04/10/2020 03:53 AM ET)
Add
Compare
Today's Range
$15.09
Now: $15.43
$16.33
50-Day Range
$13.06
MA: $16.76
$21.24
52-Week Range
$11.98
Now: $15.43
$36.91
Volume1.45 million shs
Average Volume1.95 million shs
Market Capitalization$2.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.67
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
Alkermes logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALKS
CUSIPG0176710
Phone353-1772-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.17 billion
Cash Flow$0.60 per share
Book Value$6.89 per share

Profitability

Net Income$-196,620,000.00

Miscellaneous

Employees2,235
Market Cap$2.43 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive ALKS News and Ratings via Email

Sign-up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.


Alkermes (NASDAQ:ALKS) Frequently Asked Questions

How has Alkermes' stock been impacted by COVID-19 (Coronavirus)?

Alkermes' stock was trading at $16.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ALKS stock has decreased by 5.0% and is now trading at $15.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alkermes?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 10 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Alkermes.

When is Alkermes' next earnings date?

Alkermes is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for Alkermes.

How were Alkermes' earnings last quarter?

Alkermes Plc (NASDAQ:ALKS) released its quarterly earnings results on Thursday, February, 13th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.18. The company earned $412.70 million during the quarter, compared to analysts' expectations of $404.45 million. Alkermes had a negative net margin of 16.79% and a positive return on equity of 1.58%. The business's revenue was up 30.7% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. View Alkermes' earnings history.

What guidance has Alkermes issued on next quarter's earnings?

Alkermes issued an update on its FY20 earnings guidance on Thursday, February, 13th. The company provided earnings per share (EPS) guidance of $0.25 to $0.43 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.52. The company issued revenue guidance of $1.03 billion to $1.08 billion, compared to the consensus revenue estimate of $1.06 billion.

What price target have analysts set for ALKS?

12 analysts have issued 12-month price objectives for Alkermes' stock. Their forecasts range from $16.00 to $28.00. On average, they anticipate Alkermes' stock price to reach $22.42 in the next year. This suggests a possible upside of 45.3% from the stock's current price. View analysts' price targets for Alkermes.

What are Wall Street analysts saying about Alkermes stock?

Here are some recent quotes from research analysts about Alkermes stock:
  • 1. According to Zacks Investment Research, "Alkermes reported impressive third-quarter results wherein both earnings and sales beat estimates. With increasing traction of Aristada in the market, Alkermes is emerging as a leader in the treatment of schizophrenia. This year will be an important one for the company’s late-stage pipeline owing to the planned submission of the NDA for ALKS 3831 for both schizophrenia and bipolar I disorder indications. The company also expects action on the regulatory review of the recently submitted NDA for Vumerity (diroximel fumarate) for multiple sclerosis in the fourth quarter. However, Alkermes is highly dependent on manufacturing and/or royalty revenues from partners, which is a concern. Shares have underperformed the industry year to date." (1/2/2020)
  • 2. HC Wainwright analysts commented, "Valuation Our $28 price target for Alkermes is based on our sum-of-the-parts NPV valuation based on each of the company’s marketed products and pipeline assets. Our DCF model utilizes a discount rate of 13.1% based on the company’s WACC (Beta of 1.9, equity risk premium of 6.7%)." (5/31/2019)

Has Alkermes been receiving favorable news coverage?

News stories about ALKS stock have trended very negative on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alkermes earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAlkermes.

Are investors shorting Alkermes?

Alkermes saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 6,459,600 shares, an increase of 12.7% from the February 27th total of 5,730,000 shares. Based on an average daily volume of 2,318,300 shares, the short-interest ratio is currently 2.8 days. Approximately 4.1% of the shares of the stock are short sold. View Alkermes' Current Options Chain.

Who are some of Alkermes' key competitors?

What other stocks do shareholders of Alkermes own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Netflix (NFLX), AbbVie (ABBV), Celgene (CELG), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Starbucks (SBUX), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Who are Alkermes' key executives?

Alkermes' management team includes the following people:
  • Mr. Richard F. Pops, Chairman & CEO (Age 57)
  • Dr. Floyd E. Bloom, Co-Founder & Director (Age 82)
  • Mr. James M. Frates, Sr. VP & CFO (Age 52)
  • Mr. David Joseph Gaffin, Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 47)
  • Dr. Craig C. Hopkinson, Sr. VP of Medicines Devel. & Medical Affairs and Chief Medical Officer (Age 51)

What is Alkermes' stock symbol?

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

How do I buy shares of Alkermes?

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alkermes' stock price today?

One share of ALKS stock can currently be purchased for approximately $15.43.

How big of a company is Alkermes?

Alkermes has a market capitalization of $2.43 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe. View additional information about Alkermes.

What is Alkermes' official website?

The official website for Alkermes is http://www.alkermes.com/.

How can I contact Alkermes?

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel